



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/551,152	09/25/2006	Xin-Yun Huang	2003080-0205 (SK-1071-US2)	4442
63411	7590	06/06/2008	EXAMINER	
CHOATE, HALL & STEWART LLP			HAVLIN, ROBERT H	
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH				
TWO INTERNATIONAL PLACE			ART UNIT	PAPER NUMBER
BOSTON, MA 02110			1626	
			MAIL DATE	DELIVERY MODE
			06/06/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/551,152	HUANG ET AL.
	Examiner	Art Unit
	ROBERT HAVLIN	1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 26 February 2008.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-62 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-40,43-57 and 60-62 is/are rejected.
- 7) Claim(s) 1-62 is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 28 September 2005 is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ . | 6) <input type="checkbox"/> Other: _____ . |


DETAILED ACTION

Status of the claims: Claims 1-62 are currently pending. Claim 1 was amended.

Priority: This application is a 371 of PCT/US04/09380 (03/26/2004) which claims benefit of 60/458,827 (03/28/2003) and claims benefit of 60/496,165 (08/19/2003).

Election/Restrictions

1. Applicant previously elected the following species (stated to read on claims 1-12, 14, 16-20, 27, 30, 41-62):



Because the generic claim 1 was found unpatentable, in accordance with the requirement for restriction and election of species practice, the claims are hereby restricted to the elected species.

Withdrawn Rejections

2. Claim 1 was rejected under 35 U.S.C. 102(b) as being anticipated by Takeuchi et al. (CAPLUS abstract of WO 2001046451, accession number 2001:472958). Based on the claim amendments adding a proviso removing migrastatin, this rejection is hereby withdrawn.

NEW Claim Rejections –

35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:


A person shall be entitled to a patent unless –

Art Unit: 1626


(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Nakamura et al. (Journal of Antibiotics (2002), 55(4), 442-444).

The instant claims read on a pharmaceutical composition with a compound having the following formula:



Nakamura et al. teaches the following compound:



Which reads on the claims when Y1-Y2 is (=O); X1 is O; Q is ; R6 is Me; R_{a,b,c} are H; R4 is OH; R3 is Me; R2 is H; n=2; R1 is H; R5 is Me.

Therefore, the claim is anticipated.

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:


A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Art Unit: 1626

6. Claims 1-12, 14, 16-19, 27, and 30 are rejected under 35 U.S.C. 102(a) as being anticipated by Gaul et al. (Gaul, Christoph; Danishefsky, Samuel J. Tetrahedron Letters (2002), 43(50), 9039-9042; listed in IDS; available online 11/9/2002).

The prior art teaches the following compound:



which is a member of the genus of claim 1.

Claim Rejections - 35 USC § 112

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 1-40, 43-57, 60-62 are rejected under 35 USC 112 1st paragraph as failing to comply with the written description requirement.

The MPEP states that the purpose of the written description requirement is to ensure that the inventor had possession, as of the filing date of the application, of the specific subject matter later claimed by him. The courts have stated:

"To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997); In re Gostelli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) ("[T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc.,

that set forth the claimed invention.” Lockwood, 107 F.3d at 1572, 41 USPQ2d at 1966.” Regents of the University of California v. Eli Lilly & Co., 43 USPQ2d 1398.

Further, for a broad generic claim, the specification must provide adequate written description to identify the genus of the claim. In *Regents of the University of California v. Eli Lilly & Co.* the court stated:

“A written description of an invention involving a chemical genus, like a description of a chemical species, ‘requires a precise definition, such as by structure, formula, [or] chemical name,’ of the claimed subject matter sufficient to distinguish it from other materials.” *Fiers*, 984 F.2d at 1171, 25 USPQ2d 1601; *In re Smythe*, 480 F.2d 1376, 1383, 178 USPQ 279, 284985 (CCPA 1973) (“In other cases, particularly but not necessarily, chemical cases, where there is unpredictability in performance of certain species or subcombinations other than those specifically enumerated, one skilled in the art may be found not to have been placed in possession of a genus . . . ”) *Regents of the University of California v. Eli Lilly & Co.*, 43 USPQ2d 1398.

The MPEP states that for a generic claim the genus can be adequately described if the disclosure presents a sufficient number of representative species that encompass the genus. MPEP § 2163. If the genus has a substantial variance, the disclosure must describe a sufficient variety of species to reflect the variation within that genus. See MPEP § 2163. Although the MPEP does not define what constitute a sufficient number of representative species, the courts have indicated what do not constitute a representative number of species to adequately describe a broad genus. In *Gostelli*, the courts determined that the disclosure of two chemical compounds within a subgenus did not describe that subgenus. *In re Gostelli*, 872, F.2d at 1012, 10 USPQ2d at 1618.


The Guidelines for Examination of Patent Applications Under 35 USC 112, ¶1, “Written Description” Requirement (Federal Register, Vol. 66, No. 4, pg. 1105, column 3), in accordance with MPEP § 2163, specifically state that for each claim drawn to a genus the written description requirement may be satisfied through sufficient description of a representative number of species by a) actual reduction to practice; b) reduction to drawings or structural chemical formulas; c) disclosure of relevant, identifying characteristics (ie. structure) by functional characteristics coupled with a known or

disclosed correlation between function and structure. The analysis of whether the specification complies with the written description requirement calls for the examiner to compare the scope of the claim with the scope of the description to determine whether applicant has demonstrated possession of the claimed invention (Federal Register, Vol. 66, No. 4, p. 1105, 3rd column, 3rd paragraph). Below is such comparison.

It is noted that in the following the comparison is focused on products and not method of use. It is to be understood, however, that a *prima facie* conclusion of lack of written description for product implies the same conclusion for the process of use. In other words, the process of use cannot be practiced in absence of the product.

I. Scope of Claims (based on elected subject matter)

Compounds of Formula I :




The following variables are claimed *broader* than what is supported by the disclosure (see below section II):

R ₁ and R ₂ :	for claims 1-15, 17-29, 43-57, 60-62
R ₅ and R ₆ :	for claims 1-16, 18-36, 39-40, 43-57, 60-62
R ₃ :	for claims 1-17, 20-40, 43-57, 60-62
R ₄ :	for claims 1-19, 21-40, 43-57, 60-62
R _a , R _b , and R _c :	for claims 1-11, 16-20, 23-24, 27, 43-57, 60-62
Y ₁ , Y ₂ :	for claims 1-27, 43-57, 60-62
n	for claims 1-13, 16-30, 32, 34, 35, 37, 39, 43-57, 60-62
X ₁ :	for claims 1-29, 43-57, 60-62
Q:	for claims 1-25, 27-38, 43-57, 60-62

II. Scope of Disclosure


Reduction to Practice:

The following compounds are disclosed in the specification in support of the claims:



The compounds reduced to practice support the following definitions:

R_1, R_2, R_5, R_6 :	H, or lower alkyl
R_3 :	H, or lower alkyl
R_4 :	H, OH, -O(lower alkyl)
R_a, R_b , and R_c :	H
Y_1, Y_2 :	H, Me, combined to (=O, =N(as above)), OH, CF ₃ , -O(lower alkyl)
n	3
X_1 :	O, NH, CH ₂



Reduction to Structural or Chemical Formulas:

The only disclosure, in addition to the species reduced to practice, is in form of a list of possible substituents for each variable. This type of disclosure is not viewed to be a representation of any of the species it entails. A “laundry list” disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not “reasonably lead” those skilled in the art to any particular species. MPEP 2163.I.A. and *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996). Therefore, there is no disclosure of species (eg. by reduction to structural/chemical formulas) in addition to those reduced to practice.

Correlation between Structure and Function:

Furthermore, the instant specification does not disclose any correlation between function and structure. Thus, it is not understood what specific structural elements (pertaining to variables) are essential for the activity of the instantly claimed compounds.

III. Analysis of Fulfillment of Written Description Requirement:

In the absence of a correlation between structure (as it pertains to the variables) and function, it is not possible to predict what modifications will allow for the preservation of the desired activity.

In conclusion: (i) substantial structural variation exists in the genus/subgenus embraced by claims 1-40, 43-57, 60-62; (ii) disclosure of species supporting genus is limited to compounds reduced to practice, which scope is not commensurate with the scope of genus/subgenus claimed; (iii) common structural attributes of the claimed genus/subgenus, combined with a correlation

between structure and function, is neither disclosed in the instant application nor commonly known in the art. Thus, the specification fails to provide adequate written description for the genus of compounds claimed and does not reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the entire scope of the claimed invention.

9. Claims 48-62 are rejected under 35 U.S.C. 112, first paragraph, because the specification does not reasonably provide enablement for treating breast tumor metastasis in a subject. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosures in the specification coupled with information known in the art without undue experimentation (*United States v. Telectronics*, 8 USPQ2d 1217 (Fed. Cir. 1988)). Whether undue experimentation is needed is not based upon a single factor but rather is a conclusion reached by weighing many factors. These factors were outlined in *Ex parte Forman*, 230 USPQ 546 (Bd. Pat. App. & Int. 1986) and again in *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988) and include the following:

Nature of Invention. The nature of the invention involves the use of pharmaceutical agents in treating patients.

Scope of the Invention. The scope of the invention in the claims includes the treatment of breast tumor metatasis with a broad genus of compounds of formula I.

State of the Art and Level of Skill in the Art. Although the level of skill in the art is very high, the successful treatment of diseases in cases where the underlying causes is not completely understood, as discussed in Vant Veer et al. (Nature Medicine 9, 999 - 1000 (2003)), is very rare and highly unpredictable.

Number of Working Examples and Guidance Provided by Applicant. The applicant provides no working examples of the method in a subject.

Unpredictability of the Art and Amount of Experimentation. The art of using pharmaceuticals to treat disease is unpredictable. In nearly every case, the skilled artisan could not predict *a priori* whether a given pharmaceutical would treat any given disease. Furthermore, there would be a huge amount of experimentation required in order to arrive at the appropriate formulation, protocol, and determination of effectiveness before the skilled artisan could claim to have treated any disease with a given pharmaceutical.

Considering the above factors, the claims are clearly not enabled for the methods of treating breast tumor metastasis in a subject.

10. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

11. Claims 43 and 44 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claim recites "an amount effective to inhibit metastasis/angiogenesis" yet it is not clear what this amount is. These compounds are not being evaluated for therapeutic utility and they are drawn to compositions.

Functional language as that of the instant claims carries no patentable weight in claims for compositions of matter, see Union Oil Co. of California v. Atlantic Richfield Co., 54 USPQ2d 1227, where "composition claims cannot, as the appellant refiners argue, embrace only certain uses of that composition. (citing In Re Spada). Otherwise these composition claims would mutate into method claims." It is recommended that applicant cancel the intended use recitation. In essence the removal of the functional language allows for broader patent protection, since a claim which would cover a composition with any amount of a compound is unarguably much broader than a composition containing the narrower "amount effective to inhibit".

Claim Objections

Claims 1-62 continue to be objected to for reading on non-elected subject matter and being dependent on a rejected base claim.

Conclusion

No claim is in condition for allowance.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT HAVLIN whose telephone number is (571)272-9066. The examiner can normally be reached on Mon. - Fri., 7:30am-5pm EST.

If attempts to reach the examiner by telephone are unsuccessful the examiner's supervisor, Joe McKane can be reached at (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

Art Unit: 1626

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Robert Havlin/
Examiner, Art Unit 1626

/Rebecca L Anderson/
Primary Examiner, Art Unit 1626